This paper outlines the joint research project “Increasing cancer treatment efficacy using 3D brachytherapy” co-funded in the FP7, according to the iMERA-Plus Grant Agreement No. 217257 between the EC and EURAMET e. V. (European Association of National Metrology Institutes). The project brings together the capabilities of ten major European National Metrology Institutes in the ionizing radiation field and it is focused on the targeted programme “Health”. It aims at establishing across Europe a more accurate metrological basis in brachytherapy by developing methods for the direct measurement of the quantity absorbed dose to water in brachytherapy dosimetry with an uncertainty on the dose delivered to the target volume less than 5% (k=1) at clinical level. In fact, in the current brachytherapy practice, the procedures to determine the absorbed dose imparted to the patient are affected by an uncertainty that could reduce the treatment success. Most of this uncertainty is due to a lacking metrology. No absorbed-dose primary standards are so far available to assure direct traceability in dosimetry of brachytherapy sources. In order to optimize the brachytherapy treatments there is also a need for more accurate dosimetry with high spatial resolution. The present research project is expected to increase the accuracy of brachytherapy to a level comparable to that typical of radiotherapy with external accelerator beams.

An attempt is made to give a sort of classification of the median nail dystrophies. 6 own cases are reported. As there are many morphological transitional forms, it is for the present recommended to call all those forms dystrophia unguium mediana canaliformis.